Delving into the Latest Updates on Rimantadine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Rimantadine, Rimantadine Hydrochloride Granules, Rimantadine Hydrochloride Syrup

+ [13]

Target

M2 protein

Mechanism

M2 protein inhibitors(Matrix protein 2 inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza A virus infection

Inactive Indication-

Originator Organization

Sun Pharmaceutical Industries Ltd.

Active Organization

Apeloa Pharmaceutical Co., Ltd.

Inactive Organization

Sun Pharmaceutical Industries, Inc.Forest Laboratories, Inc.

Drug Highest PhaseApproved

First Approval Date

US (17 Sep 1993),

Influenza A virus infection

Regulation-

Login to view timeline

Structure

Molecular FormulaC12H21N

InChIKeyUBCHPRBFMUDMNC-UHFFFAOYSA-N

CAS Registry13392-28-4

View All Structures (2)

Hepatitis C virus is one of the leading causes of liver failure and liver cancer worldwide. Current treatment of hepatitis C infection is only successful in about half of those who are eligible. The current treatment aims to boost the host immune system but does not directly act on the virus. Many drugs are in various stages of development that target the virus directly - their specific mode of action is confirmed by showing the virus is forced to adapt in the presence of the drug. As with many viruses, treating with only one specific drug would quickly lead to the virus adapting and becoming resistant. We therefore need to find new combinations of directly acting drugs. Rimantadine has already been shown in the laboratory to target hepatitis C directly. We have designed this study to see if it happens in real life as well. If so, we could use rimantadine to help fight hepatitis c more effectively.

Start Date01 May 2012

Sponsor / Collaborator

Leeds Teaching Hospitals NHS Trust

[+1]

NCT01172847 / CompletedPhase 1

An Open-label, Multiple Dose, Randomized, Three-period Crossover Study in Healthy Subjects to Evaluate the Effect of Co-administration of Oseltamivir (Ro 64-0796) 75 mg Twice Daily and Rimantadine 100 mg Twice Daily on the Pharmacokinetic Properties of Oseltamivir and Rimantadine.

This open label, randomized, three-period crossover study will evaluate the effect of co-administration of Tamiflu (oseltamivir) and rimantadine on the pharmacokinetics of Tamiflu and rimantadine. Healthy volunteers will receive multiple oral doses of Tamiflu, rimantadine or Tamiflu plus rimantadine in random order, with a minimum wash-out period of 7 days between treatments. Anticipated time on study is up to 11 weeks.

Start Date01 Aug 2009

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

100 Clinical Results associated with Rimantadine Hydrochloride

Login to view more data

100 Translational Medicine associated with Rimantadine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Rimantadine Hydrochloride

Login to view more data

711

Literatures (Medical) associated with Rimantadine Hydrochloride

01 Jul 2024·Heliyon

Development and validation of Mayaro virus with luciferase reporter genes as a tool for antiviral assays

Article

Author: Zhang, Ya-Nan ; Jardim, Ana Carolina Gomes ; Cassani, Natasha Marques ; Costa Oliveira, Ana Laura ; Corbi, Pedro Paulo ; Marinho, Mikaela Dos Santos ; Santos, Igor Andrade ; Dos Santos Pereira, Anna Karla ; Zhang, Bo

Arboviruses are etiological agents in an extensive group of emerging diseases with great clinical relevance in Brazil, due to the wide distribution of their vectors and the favorable environmental conditions. Among them, the Mayaro virus (MAYV) has drawn attention since its emergence as the etiologic agent of Mayaro fever, a highly debilitating disease. To study viral replication and identify new drug candidates, traditional antiviral assays based on viral antigens and/or plaque assays have been demonstrating low throughput, making it difficult to carry out larger-scale assays. Therefore, we developed and characterized two DNA-launched infectious clones reporter viruses based on the MAYV strain BeAr 20290 containing the reporter genes of firefly luciferase (FLuc) and nanoluciferase (NLuc), designated as MAYV-firefly and MAYV-nanoluc, respectively. The viruses replicated efficiently with similar properties to the parental wild-type MAYV, and luminescence expression levels reflected viral replication. Reporter genes were also preserved during passage in cell culture, remaining stably expressed for one round of passage for MAYV-firefly and three rounds for MAYV-nanoluc. Employing the infectious clone, we described the effect of Rimantadine, an FDA-approved Alzheimer's drug, as a repurposing agent for MAYV but with a broad-spectrum activity against Zika virus infection. Additionally, we validated MAYV-nanoluc as a tool for antiviral drug screening using the compound EIDD-2749 (4'-Fluorouridine), which acts as an inhibitor of alphavirus RNA-dependent RNA polymerase.

01 Jun 2024·Current Medicinal Chemistry

Antiviral Compounds to Address Influenza Pandemics: An Update from 2016-2022

Review

Author: Romeo, Roberto ; Iannazzo, Daniela ; Legnani, Laura ; Chiacchio, Maria Assunta ; Giofrè, Salvatore V

Abstract:In recent decades, the world has gained experience of the dangerous effects of pandemic events caused by emerging respiratory viruses. In particular, annual epidemics of influenza are responsible for severe illness and deaths. Even if conventional influenza vaccines represent the most effective tool for preventing virus infections, they are not completely effective in patients with severe chronic disease and immunocompromised and new small molecules have emerged to prevent and control the influenza viruses. Thus, the attention of chemists is continuously focused on the synthesis of new antiviral drugs able to interact with the different molecular targets involved in the virus replication cycle. To date, different classes of influenza viruses inhibitors able to target neuraminidase enzyme, hemagglutinin protein, Matrix-2 (M2) protein ion channel, nucleoprotein or RNAdependent RNA polymerase have been synthesized using several synthetic strategies comprising the chemical modification of currently used drugs. The best results, in terms of inhibitory activity, are in the nanomolar range and have been obtained from the chemical modification of clinically used drugs such as Peramivir, Zanamivir, Oseltamir, Rimantadine, as well as sialylated molecules, and hydroxypyridinone derivatives. The aim of this review is to report, covering the period 2016-2022, the most recent routes related to the synthesis of effective influenza virus inhibitors.

01 Mar 2024·European Journal of Medicinal Chemistry

Tackling Influenza A virus by M2 ion channel blockers: Latest progress and limitations

Review

Author: Sakharam, Kakade Aditi ; Kumar, Gautam

Influenza outbreaks cause pandemics in millions of people. The treatment of influenza remains a challenge due to significant genetic polymorphism in the influenza virus. Also, developing vaccines to protect against seasonal and pandemic influenza infections is constantly impeded. Thus, antibiotics are the only first line of defense against antigenically distinct strains or new subtypes of influenza viruses. Among several anti-influenza targets, the M2 protein of the influenza virus performs several activities. M2 protein is an ion channel that permits proton conductance through the virion envelope and the deacidification of the Golgi apparatus. Both these functions are critical for viral replication. Thus, targeting the M2 protein of the influenza virus is an essential target. Rimantadine and amantadine are two well-known drugs that act on the M2 protein. However, these drugs acquired resistance to influenza and thus are not recommended to treat influenza infections. This review discusses an overview of anti-influenza therapy, M2 ion channel functions, and its working principle. It also discusses the M2 structure and its role, and the change in the structure leads to mutant variants of influenza A virus. We also shed light on the recently identified compounds acting against wild-type and mutated M2 proteins of influenza virus A. These scaffolds could be an alternative to M2 inhibitors and be developed as antibiotics for treating influenza infections.

100 Deals associated with Rimantadine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00901	Rimantadine Hydrochloride	J05AC02	DB00478

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Influenza A virus infection	CN	Apeloa Pharmaceutical Co., Ltd.	01 Jan 2001

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01172847 (CTgov)	Phase 1	-	24	Oseltamivir (Oseltamivir)	kdeklenimi(hiiljporvt): mean exposure ratio = 0.98 (90% CI, 0.91 - 1.05) View more	-	21 Mar 2016
				Oseltamivir+Rimantadine (Oseltamivir + Rimantadine)